Volume | 240 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Nurix Therapeutics Inc | NRIX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
13.75 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
10 | 240 | - | 4.22 - 18.12 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
08:05:13 | 15 | $ 13.69 | USD |
Nurix Therapeutics (NRIX) Options Flow Summary
Nurix Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
672.29M | 48.89M | - | 76.99M | -143.95M | -2.94 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Nurix Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRIX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 14.11 | 14.84 | 12.945 | 14.00 | 899,175 | -0.34 | -2.41% |
1 Month | 14.54 | 18.12 | 12.945 | 15.29 | 1,379,586 | -0.77 | -5.30% |
3 Months | 7.94 | 18.12 | 7.83 | 13.49 | 1,042,120 | 5.83 | 73.43% |
6 Months | 4.60 | 18.12 | 4.22 | 10.98 | 884,456 | 9.17 | 199.35% |
1 Year | 10.34 | 18.12 | 4.22 | 10.34 | 611,546 | 3.43 | 33.17% |
3 Years | 30.94 | 37.425 | 4.22 | 15.02 | 479,374 | -17.17 | -55.49% |
5 Years | 20.25 | 52.38 | 4.22 | 17.63 | 445,627 | -6.48 | -32.00% |
Nurix Therapeutics Description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. |